Jeffrey W. Jacobs
Chief Tech/Sci/R&D Officer chez FULCRUM THERAPEUTICS, INC.
Profil
Jeffrey W.
Jacobs is currently the Chief Scientific Officer at Fulcrum Therapeutics, Inc. Prior to his current position, he was the Chief Scientific Officer at Goldfinch Bio, Inc. and Vice President-Medicinal Chemistry at Ardelyx, Inc. He also held senior positions in development chemistry at Sunesis Pharmaceuticals, Inc. and Affymax, Inc. Additionally, he worked as a Principal at Vicuron Pharmaceuticals LLC and The Damon Runyon Cancer Research Foundation.
Jacobs received his undergraduate degree from Gonzaga University and his doctorate from the University of California, Berkeley.
Postes actifs de Jeffrey W. Jacobs
| Sociétés | Poste | Début |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/12/2022 |
Anciens postes connus de Jeffrey W. Jacobs
| Sociétés | Poste | Fin |
|---|---|---|
| ARDELYX, INC. | Chief Tech/Sci/R&D Officer | 01/11/2021 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2008 |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
The Damon Runyon Cancer Research Foundation
 The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY. | Corporate Officer/Principal | - |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Corporate Officer/Principal | - |
Formation de Jeffrey W. Jacobs
| Gonzaga University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AFFYMAX, INC. | Health Technology |
| ARDELYX, INC. | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
The Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY. | Commercial Services |
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Health Technology |
